{"title":"Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer.","authors":"Lei-Jie Dai, Yu-Wei Li, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang","doi":"10.20892/j.issn.2095-3941.2023.0286","DOIUrl":null,"url":null,"abstract":"The concept of antibody–drug conjugations (ADCs) can be tracked back to the early 20 th century when the renowned immunologist, Paul Ehrlich, proposed the idea of a “magic bullet”, which utilizes ADCs for targeted destruction of micro-organisms and tumor cells 1 . After nearly one century of development, ADCs have emerged as a rather promising approach in the treatment of cancer, especially breast cancer, which is the most common malignant tumor in women 2 . Human epidermal growth factor receptor 2 ( HER2 ), also known as Erb-B2 receptor tyrosine kinase 2 ( ERBB2 ), is a crucial molecular classifier for breast cancer. The HER2 status is determined using immunohistochemistry (IHC) and in situ hybridization (ISH) in pathology laboratories. Approximately 15% of breast cancer patients exhibit HER2 overexpression and are thus defined as HER2-positive breast cancers. HER2 was a pivotal driver and therapeutic target in these patients 3 . HER2 is not considered to be a driving factor and is conventionally not targetable for breast cancers that display low-to-moderate HER2 expression (usually referred to as HER2-low breast cancers) 4 . The emergence of next-generation ADCs, represented by trastuzumab deruxtecan [T-DXd (also called DS-8201)], has revolutionized the precise classification and treat-ment of HER2-expressing breast cancer, including both HER2-overexpressing HER2-positive breast cancers and HER2-moderately expressed","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618949/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2023.0286","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The concept of antibody–drug conjugations (ADCs) can be tracked back to the early 20 th century when the renowned immunologist, Paul Ehrlich, proposed the idea of a “magic bullet”, which utilizes ADCs for targeted destruction of micro-organisms and tumor cells 1 . After nearly one century of development, ADCs have emerged as a rather promising approach in the treatment of cancer, especially breast cancer, which is the most common malignant tumor in women 2 . Human epidermal growth factor receptor 2 ( HER2 ), also known as Erb-B2 receptor tyrosine kinase 2 ( ERBB2 ), is a crucial molecular classifier for breast cancer. The HER2 status is determined using immunohistochemistry (IHC) and in situ hybridization (ISH) in pathology laboratories. Approximately 15% of breast cancer patients exhibit HER2 overexpression and are thus defined as HER2-positive breast cancers. HER2 was a pivotal driver and therapeutic target in these patients 3 . HER2 is not considered to be a driving factor and is conventionally not targetable for breast cancers that display low-to-moderate HER2 expression (usually referred to as HER2-low breast cancers) 4 . The emergence of next-generation ADCs, represented by trastuzumab deruxtecan [T-DXd (also called DS-8201)], has revolutionized the precise classification and treat-ment of HER2-expressing breast cancer, including both HER2-overexpressing HER2-positive breast cancers and HER2-moderately expressed
期刊介绍:
Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.